Oct 26, 09
|
| NEW STORY |
| 08:00 ET |
PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in Patients with Hemophilia
|
 |
Sep 10, 09
|
| 08:00 ET |
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
|
|
Sep 02, 09
|
| 08:00 ET |
PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
|
|
| 08:00 ET |
PTC Therapeutics Announces Drug Discovery Collaboration With Roche
|
|
Aug 10, 09
|
| 08:00 ET |
PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
|
|
Jul 27, 09
|
| 08:00 ET |
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
|
|
Jun 15, 09
|
| 08:00 ET |
PTC Therapeutics Receives $2.6 Million in Government Grants
|
|
Jun 01, 09
|
| 08:00 ET |
PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations
|
|
May 12, 09
|
| 08:00 ET |
PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
|
|
Feb 03, 09
|
| 08:00 ET |
PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
|
|
Dec 18, 08
|
| 08:00 ET |
PTC Therapeutics Initiates Two Clinical Trials of PTC299 in Cancer Patients
|
|
Oct 24, 08
|
| 09:00 ET |
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
|
|
Sep 30, 08
|
| 09:30 ET |
PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
|
|
Aug 20, 08
|
| 18:30 ET |
PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
|
|
Jul 28, 08
|
| 09:30 ET |
PTC Therapeutics Honored for Patient Advocacy Efforts by the Genetic Alliance
|
|
Jul 16, 08
|
| 08:00 ET |
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
|
|
Jun 12, 08
|
| 08:30 ET |
PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
|
|
May 30, 08
|
| 06:15 ET |
PTC124 Featured at Third Annual Congress of Myology
|
|
May 21, 08
|
| 08:30 ET |
PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
|
|
Apr 23, 08
|
| 08:00 ET |
PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
|
|
Feb 04, 08
|
| 17:00 ET |
PTC Therapeutics Announces Publication of Preclinical Data in PNAS
|
|
Dec 17, 07
|
| 08:00 ET |
PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
|
|
Dec 06, 07
|
| 09:00 ET |
PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation
|
|
Oct 18, 07
|
| 09:00 ET |
PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
|
|
Oct 11, 07
|
| 16:45 ET |
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
|
|
Oct 05, 07
|
| 11:30 ET |
PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
|
|
Sep 13, 07
|
| 08:00 ET |
PTC Therapeutics Announces $20 Million Strategic Investment From Celgene Corporation
|
|
Aug 02, 07
|
| 08:00 ET |
PTC Therapeutics Appoints Theresa Natalicchio as Senior Vice President of Marketing and Sales
|
|
Jul 10, 07
|
| 08:00 ET |
PTC Therapeutics Announces $15.4 Million NIH Research Grant for Duchenne Muscular Dystrophy
|
|
Jun 26, 07
|
| 08:00 ET |
PTC Therapeutics Appoints Manal Morsy, M.D., PH.D. as Vice President of Regulatory Affairs
|
|
Jun 03, 07
|
| 09:00 ET |
PTC Therapeutics Presents Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 43rd American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 04, 07
|
| 08:00 ET |
PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
|
|
May 02, 07
|
| 08:00 ET |
PTC Therapeutics Announces Promotion of Neil Almstead to Senior Vice President of Chemistry and CMC
|
|
Apr 23, 07
|
| 08:00 ET |
Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
|
|
Apr 20, 07
|
| 08:00 ET |
PTC Therapeutics Withdraws IPO Registration Statement
|
|
Jan 08, 07
|
| 08:00 ET |
PTC Therapeutics Announces Strategic Drug Discovery Collaboration with Pfizer Utilizing PTC's GEMS Technology Platform
|
|
Nov 07, 06
|
| 08:00 ET |
PTC Therapeutics Initiates A Phase 1 Multiple-Dose Study of Its Novel VEGF Inhibitor, PTC299
|
|
Nov 03, 06
|
| 10:30 ET |
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
|
|
Oct 21, 06
|
| 14:00 ET |
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
|
|
Oct 19, 06
|
| 08:00 ET |
FDA Awards PTC Therapeutics Orphan Products Development Grant for the Development of PTC124 in Duchenne Muscular Dystrophy
|
|
Oct 02, 06
|
| 08:00 ET |
PTC Therapeutics Announces $17.2 Million Award From the United States Defense Threat Reduction Agency
|
|
Sep 26, 06
|
| 08:00 ET |
PTC Therapeutics Receives Department of Defense Clinical Translational Research Award
|
|
Jun 12, 06
|
| 08:00 ET |
PTC Therapeutics and CV Therapeutics Announce Collaboration and License Arrangement
|
|
May 12, 06
|
| 08:00 ET |
PTC Therapeutics Initiates Phase 1a Clinical Trial of PTC299
|
|
Apr 21, 06
|
| 08:05 ET |
PTC Therapeutics Announces Promotion of Claudia Hirawat
|
|
Apr 04, 06
|
| 08:19 ET |
PTC Therapeutics Announces Interim Phase 2 Results of PTC124 in Cystic Fibrosis
|
|
Mar 31, 06
|
| 18:05 ET |
PTC Therapeutics Files for Initial Public Offering
|
|
Mar 30, 06
|
| 07:03 ET |
PTC Therapeutics Receives Fast Track Designation for PTC124 in the Treatment of Duchenne Muscular Dystrophy
|
|
Jan 27, 06
|
| 08:02 ET |
PTC Therapeutics Initiates Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
|
|
Dec 22, 05
|
| 08:02 ET |
PTC Therapeutics Initiates Second Phase 2 Study of PTC124 in Patients with Cystic Fibrosis in Israel
|
|
Dec 19, 05
|
| 08:05 ET |
PTC Therapeutics Names David P. Southwell to Its Board of Directors
|
|
Dec 06, 05
|
| 08:14 ET |
FDA's Office of Orphan Products Development Awards PTC Therapeutics a Grant to Support Clinical Development of PTC124 for the Treatment of Nonsense-Mutation-Mediated Cystic Fibrosis
|
|
| 08:03 ET |
PTC Therapeutics Initiates Phase 2 Study of PTC124 in Cystic Fibrosis
|
|
Nov 10, 05
|
| 08:12 ET |
PTC Therapeutics Raises $26.6 Million in Private Placement Financing
|
|
Jul 07, 05
|
| 08:06 ET |
European Medicines Agency (EMEA) Grants PTC Therapeutics Orphan Drug Designation for PTC124 for the Treatment of Duchenne Muscular Dystrophy and Cystic Fibrosis
|
|
Jun 29, 05
|
| 08:02 ET |
PTC Therapeutics Presents Data From Phase 1 Studies and Design of Phase 2 Studies for PTC124 at the 28th European Cystic Fibrosis Conference
|
|
May 18, 05
|
| 08:31 ET |
PTC Therapeutics Announces Promotion of William Baird to Chief Financial Officer
|
|
Apr 21, 05
|
| 08:20 ET |
PTC Therapeutics Receives $1.5 Million Grant from Muscular Dystrophy Association
|
|
Apr 11, 05
|
| 09:06 ET |
PTC Therapeutics Presents Data From Phase 1 Multiple-Dose Study of PTC124 at the 2005 American Academy of Neurology Meeting
|
|
Mar 31, 05
|
| 13:25 ET |
PTC Therapeutics Receives Fast Track Designation for PTC124
|
|